^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:Cyramza (ramucirumab) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    12/19/2014
    Excerpt:
    Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
    Secondary therapy:
    FOLFIRI
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/21/2014
    Excerpt:
    CYRAMZA® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:...in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
    Secondary therapy:
    FOLFIRI
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Colorectal cancer...the panel added ramucirumab as a second-line treatment option in combination with FOLFIRI or irinotecan following progression on therapy not containing irinotecan.
    Secondary therapy:
    irinotecan; FOLFIRI